By

Highlighted Pill Medicine Drug

Anti-hyperglycemic medications are used to lower blood sugar levels in people with high blood sugar, or hyperglycemia. These medications can be used to treat conditions such as diabetes, prediabetes, and gestational diabetes. They work by decreasing the amount of sugar produced by the liver, increasing the sensitivity of muscle and fat cells to insulin, or helping the body use sugar more effectively.

if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[300,250],’scitechdaily_com-box-3′,’ezslot_3′,102,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-box-3-0’);

The University of Arizona Center for Innovation in Brain Science conducted a study to investigate whether taking medication for Type 2 diabetes increases the likelihood of developing multiple sclerosis.

According to a study from the University of Arizona Health Sciences, people over the age of 45 with Type 2 diabetes who were treated with anti-hyperglycemic medications had a higher risk of developing multiple sclerosis, particularly among women. However, the study also found that in people under the age of 45, anti-hyperglycemic exposure actually reduced the risk of multiple sclerosis.

if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[580,400],’scitechdaily_com-medrectangle-3′,’ezslot_0′,110,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-medrectangle-3-0’);

“Our findings reinforce the need for a precision medicine approach to preventing MS in these vulnerable populations,” said lead researcher Kathleen Rodgers, Ph.D., associate director of translational neuroscience at the Center for Innovation in Brain Science.

try{window._mNHandle.queue.push(function(){window._mNDetails.loadTag(“974871025″,”600×250″,”974871025”);});}
catch(error){}

Multiple sclerosis (MS) is an unpredictable autoimmune neurological disorder that affects the central nervous system and leads to severe physical and cognitive disability. It is estimated that nearly 1 million adults in the U.S. and more than 2.8 million worldwide are living with MS.

For people with Type 2 diabetes, there is mounting evidence linking metabolic disorders and MS through a common driver of increased autoimmunity. This brings into question the impact of anti-hyperglycemic therapeutics used to treat Type 2 diabetes, including insulin, on the incidence of MS.

if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[250,250],’scitechdaily_com-medrectangle-4′,’ezslot_5′,111,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-medrectangle-4-0’);if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[250,250],’scitechdaily_com-medrectangle-4′,’ezslot_6′,111,’0′,’1′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-medrectangle-4-0_1’);.medrectangle-4-multi-111{border:none!important;display:block!important;float:none!important;line-height:0;margin-bottom:15px!important;margin-left:auto!important;margin-right:auto!important;margin-top:15px!important;max-width:100%!important;min-height:250px;min-width:250px;padding:0;text-align:center!important}

“Previous research has shown a neuroprotective effect of anti-hyperglycemic medications in <span class=glossaryLink aria-describedby=tt data-cmtooltip="

Alzheimer’s
Alzheimer's disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer's disease, but there are medications that can help ease the symptoms.

” data-gt-translate-attributes='[{“attribute”:”data-cmtooltip”, “format”:”html”}]’>Alzheimer’s disease and other related dementias,” Dr. Rodgers said. “For MS, we wanted to further examine age and sex differences, particularly among men and women under 45 with Type 2 diabetes.”

They found that men older than 45 years old had a slightly significant increase of MS risk and women older than 45 years exhibited a significant increase in MS incidence after anti-hyperglycemic exposure. In addition to age differences, the risk analysis by drug class showed that exposure to insulin in patients older than 45 years old was associated with a greater increased risk compared with other therapies.

In patients younger than 45, anti-hyperglycemic exposure was protective against the development of MS.

The study utilized a U.S.-based insurance claims database of 151 million participants to identify more than 5 million patients with a diagnosis of Type 2 diabetes and either early-onset or late-onset MS. Researchers segmented the data by age – patients diagnosed with Type 2 diabetes prior to or after age 45 – and sex to decode the factors driving MS risk in both populations, especially in women over 45 years of age.

if(typeof ez_ad_units!=’undefined’){ez_ad_units.push([[580,400],’scitechdaily_com-box-4′,’ezslot_4′,112,’0′,’0′])};__ez_fad_position(‘div-gpt-ad-scitechdaily_com-box-4-0’);

Reference: “Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics” by Gregory L. Branigan, Georgina Torrandell-Haro, Francesca Vitali, Roberta Diaz Brinton and Kathleen Rodgers, 1 October 2022, Heliyon.
DOI: 10.1016/j.heliyon.2022.e11196

The study was funded by the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, both divisions of the National Institutes of Health.

Anti-hyperglycemic medications are used to lower blood sugar levels in people with high blood sugar, or hyperglycemia. These medications can be used to treat conditions such as diabetes, prediabetes, and gestational diabetes. They work by decreasing the amount of sugar produced by the liver, increasing the sensitivity of muscle and fat cells to insulin, or helping the body use sugar more effectively.
The University of Arizona Center for Innovation in Brain Science conducted a study to investigate whether taking medication for Type 2 diabetes increases the likelihood of developing multiple sclerosis.
According to a study from the University of Arizona Health Sciences, people over the age of 45 with Type 2 diabetes who were treated with anti-hyperglycemic medications had a higher risk of developing multiple sclerosis, particularly among women. However, the study also found that in people under the age of 45, anti-hyperglycemic exposure actually reduced the risk of multiple sclerosis.
“Our findings reinforce the need for a precision medicine approach to preventing MS in these vulnerable populations,” said lead researcher Kathleen Rodgers, Ph.D., associate director of translational neuroscience at the Center for Innovation in Brain Science.

try{window._mNHandle.queue.push(function(){window._mNDetails.loadTag(“974871025″,”600×250″,”974871025”);});}
catch(error){}

Multiple sclerosis (MS) is an unpredictable autoimmune neurological disorder that affects the central nervous system and leads to severe physical and cognitive disability. It is estimated that nearly 1 million adults in the U.S. and more than 2.8 million worldwide are living with MS.
For people with Type 2 diabetes, there is mounting evidence linking metabolic disorders and MS through a common driver of increased autoimmunity. This brings into question the impact of anti-hyperglycemic therapeutics used to treat Type 2 diabetes, including insulin, on the incidence of MS.
“Previous research has shown a neuroprotective effect of anti-hyperglycemic medications in <span class=glossaryLink aria-describedby=tt data-cmtooltip="

Alzheimer’s
Alzheimer's disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer's disease, but there are medications that can help ease the symptoms.

” data-gt-translate-attributes='[{“attribute”:”data-cmtooltip”, “format”:”html”}]’>Alzheimer’s disease and other related dementias,” Dr. Rodgers said. “For MS, we wanted to further examine age and sex differences, particularly among men and women under 45 with Type 2 diabetes.”
They found that men older than 45 years old had a slightly significant increase of MS risk and women older than 45 years exhibited a significant increase in MS incidence after anti-hyperglycemic exposure. In addition to age differences, the risk analysis by drug class showed that exposure to insulin in patients older than 45 years old was associated with a greater increased risk compared with other therapies.
In patients younger than 45, anti-hyperglycemic exposure was protective against the development of MS.
The study utilized a U.S.-based insurance claims database of 151 million participants to identify more than 5 million patients with a diagnosis of Type 2 diabetes and either early-onset or late-onset MS. Researchers segmented the data by age – patients diagnosed with Type 2 diabetes prior to or after age 45 – and sex to decode the factors driving MS risk in both populations, especially in women over 45 years of age.
Reference: “Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics” by Gregory L. Branigan, Georgina Torrandell-Haro, Francesca Vitali, Roberta Diaz Brinton and Kathleen Rodgers, 1 October 2022, Heliyon.
DOI: 10.1016/j.heliyon.2022.e11196
The study was funded by the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, both divisions of the National Institutes of Health.


Health

Global Study Finds Vast Under-Treatment of Diabetes

Health

Brain Tissue Study Uncovers New Genes Linked to Multiple Sclerosis

Health

5 Lesser-Known Symptoms of Diabetes You Probably Don’t Know About

Health

Disturbing New Research Shows Diabetes Set to Devastate India’s Metropolitan Cities

Health

The Surprising Relationship Between Cancer and Diabetes

Health

Artificial Pancreas Developed That Can Help Maintain Healthy Glucose Levels in Type 2 Diabetes Patients

Biology

New Blood Sample Detection Method for Multiple Sclerosis

Health

Medication Shows Benefits Treating Type 1 Diabetes – Delayed Disease Progression, Lowered Insulin Requirements

You should name the drugs that are suspect. And yes, Metformin is one.
Should mention drug name
Yes
Email address is optional. If provided, your email will not be published or shared.


document.getElementById(“ak_js_1”).setAttribute(“value”,(new Date()).getTime());
SciTechDaily: Home of the best science and technology news since 1998. Keep up with the latest scitech news via email or social media.
  > Subscribe Free to Email Digest

January 10, 2023

Harvard Astronomers Have Revealed the True Shape of the Milky Way’s Halo of Stars

A recent study has unveiled the true shape of the diffuse cloud of stars surrounding the disk of our galaxy, known as the stellar halo….

Read More

A recent study has unveiled the true shape of the diffuse cloud of stars surrounding the disk of our galaxy, known as the stellar halo….
January 10, 2023

Hospitals Are at Risk: Smartphone Attacks Could Release Deadly Microbes

January 10, 2023

Threatening Even Large Ships – Unraveling the Mystery of Colossal Rogue Waves

January 10, 2023

Violent Galactic Shockwave: Webb Space Telescope Reveals Sonic Boom Bigger Than the Milky Way

January 9, 2023

New Study Significantly Narrows Search for Elusive Dark Matter Particles

January 9, 2023

Scientists Successfully Edit the Genes of Nature’s Master Manipulators

January 9, 2023

Unprecedented Discovery: Astronomers Observe Most Distant Black Hole Devouring a Star

January 9, 2023

Contrary to Previous Assumptions: Forests Recovering From Logging Act as a Source of Carbon

Copyright © 1998 – 2023 SciTechDaily. All Rights Reserved.

source

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *